Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2XCT

The twinned 3.35A structure of S. aureus Gyrase complex with Ciprofloxacin and DNA

2XCT の概要
エントリーDOI10.2210/pdb2xct/pdb
関連するPDBエントリー2XCO 2XCQ 2XCR 2XCS
分子名称DNA GYRASE SUBUNIT B, DNA GYRASE SUBUNIT A, 5'-D(TP*GP*TP*GP*CP*GP*GP*T)-3', 5'-D(AP*GP*CP*CP*GP*TP*AP*G)-3', ... (7 entities in total)
機能のキーワードisomerase-dna-antibiotic complex, isomerase/dna/antibiotic
由来する生物種STAPHYLOCOCCUS AUREUS
詳細
細胞内の位置Cytoplasm (Potential): Q99XG5
タンパク質・核酸の鎖数12
化学式量合計338530.89
構造登録者
主引用文献Bax, B.D.,Chan, P.F.,Eggleston, D.S.,Fosberry, A.,Gentry, D.R.,Gorrec, F.,Giordano, I.,Hann, M.M.,Hennessy, A.,Hibbs, M.,Huang, J.,Jones, E.,Jones, J.,Brown, K.K.,Lewis, C.J.,May, E.W.,Saunders, M.R.,Singh, O.,Spitzfaden, C.,Shen, C.,Shillings, A.,Theobald, A.F.,Wohlkonig, A.,Pearson, N.D.,Gwynn, M.N.
Type Iia Topoisomerase Inhibition by a New Class of Antibacterial Agents.
Nature, 466:935-, 2010
Cited by
PubMed Abstract: Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance. Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action. Here we report the 2.1 A crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target. The inhibitor 'bridges' the DNA and a transient non-catalytic pocket on the two-fold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites. In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate. This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.
PubMed: 20686482
DOI: 10.1038/NATURE09197
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.35 Å)
構造検証レポート
Validation report summary of 2xct
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon